Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization
Launched by INSTITUTO DE OLHOS DE GOIANIA · Jan 9, 2014
Trial Information
Current as of July 24, 2025
Unknown status
Keywords
ClinConnect Summary
Twenty consecutive patients (30 eyes) with subfoveal PM-CNV, 9 of whom had been unsuccessfully treated with Visudyne PDT, were treated with IVT of 0.5mg ranibizumab. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. IVTs were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment. The follow-up period was at least 6 months
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Myopic and CNVM
- Exclusion Criteria:
- • Patients with poor compliance
- • Patients with uncontrolled diabetes and hypertension or any other medical condition that increase the risk of complications like recent history of Stroke or myocardial infraction (\< one year). (Physician clearance was obtained for all patients).
- • Age related macular degeneration with Juxtafoveal and Subfoveal CNVM: Recurrent CNVM following PDT and TTT with IVTA. Patient who could not afford PDT, Macugen or Lucentis which is FDA approved.
- • Patients who had undergone major surgery 28 days before, were excluded from the study and it was also suspended prior to elective surgery.
- • Refractory macular oedema due to vein occlusion, Pseudophakia, Clinically significant macular oedema (CSME) etc. that affects vision and does not respond adequately to usual treatment methods.
- • Proliferative diabetic retinopathy, non-resolving vitreous haemorrhage with PDR.
- • Idiopathic CNVM, Inflammatory CNVM and other conditions associated with CNVM.
About Instituto De Olhos De Goiania
Instituto de Olhos de Goiânia is a leading ophthalmic research and clinical care institution dedicated to advancing eye health through innovative research and comprehensive patient services. With a focus on clinical trials, the institute collaborates with healthcare professionals and researchers to evaluate new treatments and technologies in ophthalmology. By prioritizing patient safety and ethical standards, Instituto de Olhos de Goiânia aims to contribute significantly to the field of eye care, enhancing the quality of life for individuals with vision-related conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Goiania, Go, Brazil
Patients applied
Trial Officials
Joao J Nassaralla, Jr
Study Chair
Instituto de Olhos de Goiânia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials